Cambridge Investment Research Advisors, Inc. Horizon Therapeutics Public LTD CO Transaction History

Cambridge Investment Research Advisors, Inc.

$26 Billion
Q1 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 24, 2023	SELL	$98.98 - $115.74 $70,671 - $82,638	-714 Reduced 7.29%	9,083 $1.05 Million
Q2 2023 Jul 13, 2023	SELL	$96.34 - $112.38 $347,691 - $405,579	-3,609 Reduced 26.92%	9,797 $1.01 Million
Q1 2023 May 11, 2023	SELL	$107.32 - $113.5 $134,257 - $141,988	-1,251 Reduced 8.54%	13,406 $1.46 Million
Q4 2022 Feb 08, 2023	SELL	$62.39 - $113.8 $98,014 - $178,779	-1,571 Reduced 9.68%	14,657 $1.67 Million
Q3 2022 Oct 17, 2022	BUY	$58.92 - $84.67 $106,291 - $152,744	1,804 Added 12.51%	16,228 $1 Million

Q2 2022 Jul 13, 2022	SELL	$79.4 - $116.36 $96,312 - $141,144	-1,213 Reduced 7.76%	14,424 $1.15 Million
Q1 2022 May 12, 2022	SELL	$86.42 - $109.81 $323,297 - $410,799	-3,741 Reduced 19.31%	15,637 $1.65 Million
Q4 2021 Feb 03, 2022	BUY	$98.56 - $119.91 $91,069 - $110,796	924 Added 5.01%	19,378 $2.09 Million
Q3 2021 Nov 02, 2021	SELL	$91.91 - $110.37 $211,209 - $253,630	-2,298 Reduced 11.07%	18,454 $2.02 Million
Q2 2021 Aug 10, 2021	BUY	$86.24 - $95.92 $1.79 Million - $1.99 Million	20,752 New	20,752 $1.94 Million
Q1 2021 May 07, 2021	SELL	$71.83 - $95.48 $618,097 - $821,605	-8,605 Closed	0 $0
Q4 2020 Feb 04, 2021	BUY	$67.0 - $84.39 $216,678 - $272,917	3,234 Added 60.21%	8,605 $629,000
Q3 2020 Oct 29, 2020	BUY	$55.23 - $79.93 $296,640 - $429,304	5,371 New	5,371 $417,000
Q2 2020 Jul 27, 2020	SELL	$30.2 - $56.98 $315,982 - $596,181	-10,463 Closed	0 $0
Q1 2020 May 08, 2020	BUY	$24.87 - $38.56 $260,214 - $403,453	10,463 New	10,463 $309,000

Others Institutions Holding HZNP

# of Institutions

Shares Held

2.07M

Call Options Held

Put Options Held

20K

View Full List

About Horizon Therapeutics Public Ltd Co

Ticker HZNP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 230,384,000
Description
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines ...

More about HZNP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account